MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcard.2018.10.071

Медицинская библиотека · International journal of cardiology · 2018

Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.

Faggioni Michela, Baber Usman, Chandrasekhar Jaya, Sartori Samantha, Claessen Bimmer E, Rao Sunil V, Vogel Birgit, Effron Mark B, Poddar Kanhaiya, Farhan Serdar, Kini Annapoorna, Weintraub William, Toma Catalin, Sorrentino Sabato, Weiss Sandra, Snyder Clayton, Muhlestein Joseph B, Kapadia Samir, Keller Stuart, Strauss Craig, Aquino Melissa, Baker Brian, Defranco Anthony, Pocock Stuart, Henry Timothy, Mehran Roxana

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Clinical trial data studies suggest superiority of prasugrel over clopidogrel in patients with diabetes. However, the use, safety and efficacy profile of prasugrel in unselected diabetic patients presenting with acute coronary syndromes (ACS) remain unclear.

METHODS

PROMETHEUS was a prospective multicenter observational study of 19,919 ACS PCI patients enrolled between 2010 and 2013. The primary endpoint was 90-day major adverse cardiovascular events (MACE), comprising all-cause death, myocardial infarction, stroke or unplanned revascularization. The safety endpoint was bleeding requiring hospitalization.

RESULTS

We identified 7580 (38%) subjects with and 12,329 (62%) without diabetes. Diabetic patients were older and had significantly higher rates of cardiovascular risk factors. However, they were less likely to receive prasugrel (18.2% vs. 21.7%). Use of prasugrel did not increase with the severity of clinical presentation in diabetics, whereas, among non-diabetics, prescription of prasugrel was higher in NSTEMI and STEMI compared to unstable angina. The 90-day and 1-year adjusted risk of MACE was greater in diabetics (at 1 year: 22.7% vs. 16.5%; HR 1.22 [1.14-1.33], p < 0.001). At 1 year, the risk of bleeding was also higher in diabetics (4.9% vs. 4.1%, HR 1.19 [1.01-1.39], p = 0.035). After multivariable adjustment, use of prasugrel was associated with a lower risk of death in diabetic patients both at 90 days and 1 year.

CONCLUSIONS

Use of prasugrel in diabetic patients with PCI-treated ACS was lower than in non-diabetics despite their high-risk profile and the severity of their clinical presentation. In diabetics, prasugrel was associated with a lower adjusted risk of 90-day death compared with clopidogrel.

Для цитирования: Faggioni Michela, Baber Usman, Chandrasekhar Jaya, Sartori Samantha, Claessen Bimmer E, Rao Sunil V, Vogel Birgit, Effron Mark B, Poddar Kanhaiya, Farhan Serdar, Kini Annapoorna, Weintraub William, Toma Catalin, Sorrentino Sabato, Weiss Sandra, Snyder Clayton, Muhlestein Joseph B, Kapadia Samir, Keller Stuart, Strauss Craig, Aquino Melissa, Baker Brian, Defranco Anthony, Pocock Stuart, Henry Timothy, Mehran Roxana. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.. International journal of cardiology. 2018. DOI: 10.1016/j.ijcard.2018.10.071.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.